News

Generic Drugs

Next Phase of Pharma Growth: Generics

Michael McTague | Equities.com |

Here Come the Generics!

Investors have been rattled by many pieces of bad news for months but the massive pharmaceutical industry brings some relief. For 2022, Pfizer (PFE) is looking at an additional $20 billion in revenue over last year, actually a repeat of its 2021 versus 2020 performance. Their assets are way up and feature $31 billion in cash. Johnson and Johnson (JNJ), which is looking at more than $95 billion in revenue this year, has about the same...


Teva Is Charged By Justice Department With Conspiring To Raise Generic Drugs Prices

Reuters | Equities.com |

The U.S. Justice Department charged Teva Pharmaceutical Industries Ltd on Tuesday with conspiring with competitors to raise prices for generic drugs.

The Justice Department has been investigating allegations the company colluded with other drugmakers to push up the prices of widely used pharmaceuticals, including a high cholesterol drug.

“Today’s charge reaffirms that no company is too big to be prosecuted for its role in conspiracies that led to substantia...


Department of Justice To Charge Teva in Generic Drugs Price-Fixing Investigation

Bloomberg | Equities.com |

U.S. prosecutors are preparing to charge Teva Pharmaceutical Industries Ltd. with conspiring with competitors to raise prices for generic drugs, according to a person familiar with the matter.

The Justice Department is planning to charge Teva as soon as Tuesday after the company rebuffed a settlement that would have required paying a criminal penalty and admitting wrongdoing, said the person, who declined to be named because the matter is confidential.

Te...


Miracle Cures Come in Small Packages — Michael McTague

Michael McTague | Equities.com |

The race to find a coronavirus vaccine puts the pharmaceutical industry in the spotlight. Politicians who criticized companies that launch medical breakthroughs for making money are hoping that one of them will come up with a vaccine to put the deadly virus behind us. Able Global Partners has been in the forefront of investing in numerous Contract Development Manufacturing Organizations (CDMOs) and understands their significance. A number of comp...


Novartis To Provide 'Zero-Profit' COVID-19 Drugs To Developing Countries

Reuters | Equities.com |

Novartis’s Sandoz division will not make a profit on 15 generic drugs it is making available to developing countries to treat symptoms of COVID-19, the Swiss drugmaker said on Thursday.

Novartis said it would provide medicines ranging from antibiotics and steroids to diarrhea pills to 79 countries on the World Bank’s list of low- and lower-middle income nations.

The Basel-based drugmaker plans to maintain the zero-profit program until the pandemic ends or a vaccine or cure is found, Novartis Global Health Chief Operating Officer Lutz Hegemann said in an interview.


Mylan Prices Generic Remdesivir at $64 Per 100 Milligram Vial in India

Reuters | Equities.com |

Mylan NV said on Monday it would launch a generic version of Gilead Sciences Inc’s COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.

California-based Gilead has signed licensing deals with several generic drugmakers in an effort to make remdesivir available in 127 developing countries.

Last month, two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, also launched g...


Generic Drugmakers Sold the Vast Majority of Opioids During Overdose Crisis

AP News | Equities.com |

Mallinckrodt announced a tentative $1.6 billion settlement with state and local governments in the US over the company’s role in the epidemic.


Sponsored Financial Content

Market Movers